Vis enkel innførsel

dc.contributor.authorHussain, Akhtar
dc.contributor.authorBhowmik, Bishwajit
dc.contributor.authorMoreira, Nayla Cristina do Vale
dc.date.accessioned2020-07-09T09:39:49Z
dc.date.available2020-07-09T09:39:49Z
dc.date.created2020-05-09T13:07:38Z
dc.date.issued2020
dc.identifier.citationHussain, A., Bhowmik, B. & Moreira, N. C. do V. (2020). COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice, 162: 108142. doi:en_US
dc.identifier.issn0168-8227
dc.identifier.urihttps://hdl.handle.net/11250/2661581
dc.description.abstractAims We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management. Methods We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: “SARS-CoV-2”, “COVID-19”, “infection”, “pathogenesis”, “incubation period”, “transmission”, “clinical features”, “diagnosis”, “treatment”, “diabetes”, with interposition of the Boolean operator “AND”. Results The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug interactions might reduce adverse outcomes. Conclusions Suggestions are made on the possible pathophysiological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleCOVID-19 and diabetes : Knowledge in progressen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2020 The Author(s)en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Helsefag: 800en_US
dc.source.pagenumber9en_US
dc.source.volume162en_US
dc.source.journalDiabetes Research and Clinical Practiceen_US
dc.identifier.doi10.1016/j.diabres.2020.108142
dc.identifier.cristin1810064
dc.description.localcodeUnit Licence Agreementen_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal